Q-omics provides the consensus-scored LRRC3-DT profile across patient tissues and cancer cell-line models. LRRC3-DT expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, LRRC3-DT is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, LRRC3-DT RNA expression shows 12,704 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CHOL, KIRP, and TGCT as cancer lineages where LRRC3-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC3-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC3-DT survival associations across molecular data types. LRRC3-DT RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC3-DT RNA expression–survival associations across cancer types. High LRRC3-DT expression shows unfavorable associations in CHOL, KIRC, MESO, KIRP and UCEC, but favorable associations in LIHC. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify CHOL as the clearest survival context for LRRC3-DT RNA expression.
This table summarizes LRRC3-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC3-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC3-DT shows lower tumor expression in BRCA, STAD, CHOL and READ and higher tumor expression in KIRP and PRAD. The KIRP box plot shows higher LRRC3-DT RNA expression in tumor versus normal tissue (log2 FC = +0.199, t-test p < 0.001).
This table shows molecular features associated with LRRC3-DT in patient tissues and cancer cell lines. In patient samples, LRRC3-DT shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
